(Q39164487)

9 September 2017

title

Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience (English)

1 reference

9 September 2017

0 references

0 references

1 reference

U Kopylov

1

0 references

author name string

W Afif

2

1 reference

9 September 2017

A Cohen

3

1 reference

9 September 2017

A Bitton

4

1 reference

9 September 2017

G Wild

5

1 reference

9 September 2017

T Bessissow

6

1 reference

9 September 2017

J Wyse

7

1 reference

9 September 2017

T Al-Taweel

8

1 reference

9 September 2017

A Szilagyi

9

1 reference

9 September 2017

E Seidman

10

1 reference

9 September 2017

publication date

1 July 2014

1 reference

Journal of Crohn's and Colitis

9 September 2017

published in

1 reference

9 September 2017

volume

8

1 reference

9 September 2017

issue

11

1 reference

9 September 2017

page(s)

1516-1522

1 reference

The future of inflammatory bowel disease therapy: where do we go from here?

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2014.06.005

Assessing response and loss of response to biological therapies in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2014.06.005

Ustekinumab induction and maintenance therapy in refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2014.06.005

Review of the safety and efficacy of ustekinumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2014.06.005

Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2014.06.005

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2014.06.005

The IL-23/IL-17 axis in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2014.06.005

IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2014.06.005

Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2014.06.005

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2014.06.005

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2014.06.005

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2014.06.005

Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2014.06.005

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2014.06.005

10.1016/J.CROHNS.2014.06.005

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference